Varex Imaging Corp (VREX) · Oct 22, 2026 · Acquisition
Merger unchanged — $18.90 cash consideration; October 28 vote unchanged
Varex’s acquisition update discloses two lawsuits and 13 demand letters, but leaves the $18.90 cash merger and October 28 vote unchanged.
Varex is a medical- and industrial-imaging components maker being acquired by Teledyne, with products including X-ray tubes, digital detectors and image-processing systems. This filing does not change that strategic endpoint; it supplements the merger proxy after shareholder litigation and demand letters.
The deal terms are unchanged. Varex says the supplemental disclosures do not affect the cash consideration or the timing of the special meeting. 〔0〕 The board continues to recommend approval, so the filing is not a renegotiation or a new bid signal.
The new wrinkle is execution risk, not economics. Two shareholder complaints and 13 demand letters allege proxy disclosure deficiencies and seek corrective disclosures, damages or an injunction. Varex calls the claims meritless, but the volume of challenges adds legal friction around a transaction that was already agreed and scheduled.
Regulatory timing is now clearer, but closing remains conditional. The HSR waiting period is set to expire at 11:59 p.m. Eastern time on November 19, 2026, while the U.K. national-security review runs through November 18. 〔1〕 〔2〕 The October 28 stockholder vote therefore comes before the key regulatory endpoints.
| Merger reference | Value | Filing location |
|---|---|---|
| Cash merger consideration | $18.90/share | Evercore valuation analyses |
| Closing price on August 7, 2026 | $12.41/share | Evercore valuation analyses |
| Evercore DCF implied value | $15.00–$21.50/share | Discounted cash flow analysis |
| FY2027E EBITDA comparable-company value | $11.25–$19.50/share | Selected Publicly Traded Companies Analysis |
| Selected-transactions implied value | $13.25–$35.75/share | Selected Transactions Analysis |
| Analyst price-target range | $12.00–$22.00/share | Selected Publicly Available Share Price Targets |
Bottom line: This is mainly a procedural merger supplement: the price, vote timing and board recommendation stand, while shareholder lawsuits and outstanding regulatory reviews add some closing complexity without changing the transaction’s stated economics.
Stockholder vote, October 28, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!